Cervical Adenocarcinoma
Understanding Cervical Adenocarcinoma, including Endocervical Adenocarcinoma and Cervical Glandular Cancer, is crucial for accurate clinical documentation and medical coding. This resource provides information on diagnosis, treatment, and ICD-10 codes related to Cervical Adenocarcinoma, supporting healthcare professionals in proper documentation and coding practices. Learn about the latest clinical guidelines and best practices for managing Cervical Glandular Cancer and Endocervical Adenocarcinoma to ensure optimal patient care.
Cancer originating in the glandular cells of the cervix.
Often asymptomatic early on. Abnormal vaginal bleeding, pelvic pain, or discharge can occur.
Diagnosed through pelvic exam, Pap smear, colposcopy, and biopsy.
ICD-10 Code Families
Complete code families applicable to C53.9
When to use each related code
| Description | When to use |
|---|---|
| Cancer in the mucus-producing glands of the cervix. | Malignant tumor originating in endocervical glandular cells. Use for invasive adenocarcinoma. |
| Precancerous changes in cervical glandular cells. | Use for endocervical glandular neoplasia, not yet invasive. Includes AIS. |
| Squamous cell cancer of the cervix. | Malignant tumor originating in the squamous cells lining the cervix. Most common type of cervical cancer. |
Best-practice checklist
- ✓Cervical Adenocarcinoma ICD-10 code C53.9
- ✓Document tumor size, location, and laterality
- ✓Histological confirmation of adenocarcinoma required
- ✓Stage according to FIGO staging system
- ✓Lymph node involvement and distant metastasis status
Common pitfalls to avoid
Insufficient documentation to distinguish between adenocarcinoma in situ (AIS) and invasive adenocarcinoma impacting accurate coding and staging.
Missing laterality (right, left, bilateral, unspecified) for cervical cancer may affect treatment planning and data analysis for quality reporting.
Lack of documented HPV status or incorrect HPV code assignment can impact clinical decision-making and reimbursement linked to specific treatment pathways.
Best-practice tips
- 01Complete cervical cancer screening (Pap/HPV). Code Z12.4.
- 02Detailed colposcopy/biopsy documentation. ICD-10 C53.9, C53.8
- 03Timely referral for advanced imaging/staging. ICD-10 C53
- 04HPV vaccination: 9vHPV, 4vHPV. ICD-10 Z23
- 05Accurate coding for treatment: surgery, chemo, radiation.
Step-by-step checklist
- 1
Verify ICD-10 C53.x, C53.9 documented if suspected or confirmed Cervical Adenocarcinoma
- 2
Confirm histology report supports Cervical Adenocarcinoma diagnosis for accurate coding
- 3
Evaluate risk factors: HPV infection, smoking history documented in patient chart
- 4
Review imaging (colposcopy, MRI) findings consistent with Cervical Adenocarcinoma
- 5
Assess for relevant symptoms: abnormal bleeding, discharge, pain for clinical validation
Ready-to-paste narrative
Patient presents with concerns regarding abnormal vaginal bleeding, post-coital bleeding, and persistent watery discharge. She reports no significant pain. Physical examination reveals a friable lesion on the cervix. Pelvic examination findings suggest possible cervical adenocarcinoma. Differential diagnoses include endocervical adenocarcinoma, cervical glandular cancer, cervical squamous cell carcinoma, and cervical polyps. Given the clinical presentation and examination findings, cervical adenocarcinoma is the leading differential diagnosis. A biopsy was performed and sent for histopathological examination. Preliminary findings suggest adenocarcinoma of the cervix. Patient was counseled on the potential diagnosis of cervical adenocarcinoma, treatment options including surgery, radiation therapy, and chemotherapy, and the importance of follow-up care. Further diagnostic workup, including imaging studies such as a pelvic MRI and PET scan, will be performed to assess the extent of the disease and determine appropriate staging. The patient will be referred to a gynecologic oncologist for further management and treatment planning for cervical cancer. ICD-10 code C53.9, malignant neoplasm of cervix uteri, unspecified, is provisionally assigned pending definitive pathology results. This diagnosis may be further specified based on the final pathology report and staging. The patient understands the seriousness of the potential diagnosis and agrees to follow up for further evaluation and treatment.
Common questions and answers
What are the key differentiating features in the diagnostic workup of endocervical adenocarcinoma versus squamous cell carcinoma of the cervix?+
While both endocervical adenocarcinoma and squamous cell carcinoma affect the cervix, their diagnostic workup presents key differences. Squamous cell carcinoma is often initially suspected based on abnormal Pap smear cytology and confirmed with colposcopy and biopsy. Endocervical adenocarcinoma, however, may present with less obvious cytological changes, sometimes requiring endocervical curettage or cone biopsy for definitive diagnosis. Imaging modalities, such as MRI and PET/CT, play a more significant role in staging endocervical adenocarcinoma to assess the extent of local invasion and lymph node involvement. Immunohistochemistry can also differentiate adenocarcinoma subtypes. Consider implementing a more thorough evaluation for adenocarcinoma when clinical suspicion is high despite negative or equivocal initial cytology. Explore how advanced imaging can contribute to early and accurate diagnosis of cervical adenocarcinoma.
How does the management of stage IB1 cervical adenocarcinoma differ based on histological subtype and patient's desire for future fertility?+
Management of stage IB1 cervical adenocarcinoma is individualized based on factors such as histological subtype (e.g., mucinous, clear cell, serous) and the patient's desire for future fertility. For patients desiring fertility preservation, radical trachelectomy may be an option in select cases with tumors smaller than 2 cm and favorable histological features. However, this approach requires careful patient selection and thorough counseling regarding potential risks and oncological outcomes. For patients not desiring future fertility, radical hysterectomy with pelvic lymphadenectomy remains the standard of care. The specific extent of lymphadenectomy can be guided by surgical findings and the risk of nodal metastasis based on tumor characteristics. Learn more about the role of sentinel lymph node biopsy in staging and guiding treatment decisions for early-stage cervical cancer.
What are the latest advancements in targeted therapy and immunotherapy for recurrent or metastatic cervical adenocarcinoma based on specific molecular profiles?+
Recent advancements in targeted therapy and immunotherapy offer promising options for patients with recurrent or metastatic cervical adenocarcinoma. Molecular profiling, including PD-L1 expression testing and assessment for microsatellite instability (MSI) and specific genetic alterations, is crucial in guiding treatment decisions. Patients with PD-L1 positive tumors may benefit from immune checkpoint inhibitors such as pembrolizumab. Those with MSI-high tumors might respond to immunotherapy with pembrolizumab or dostarlimab. Targeted therapies, including bevacizumab, a VEGF inhibitor, are also incorporated into treatment regimens depending on the molecular profile and disease stage. Explore how molecular profiling can personalize therapeutic approaches for advanced cervical adenocarcinoma and optimize patient outcomes.
Clinical accuracy: This information is provided for documentation and coding guidance and should not replace professional medical judgment.
Coding standard: ICD-10-CM, current FY guidelines.